Qiagen

Founded on November 29, 1984, QIAGEN N.V. is a Netherlands-based biotechnology company with its corporate headquarters in Venlo and operational headquarters in Hilden, Germany. The company’s core mission is to provide Sample to Insight solutions that transform biological materials into valuable molecular insights. QIAGEN serves a diverse range of markets including Molecular Diagnostics, Applied Testing, Pharma, and Academia, offering products and services that aid in human healthcare, forensics, veterinary testing, food safety, pharmaceutical research, and life sciences research.

Notable affiliated people include founders Metin Colpan, Karsten Henco, and Jürgen Schumacher, with Thierry Bernard serving as CEO and Lawrence A. Rosen as chairman of the supervisory board. QIAGEN is publicly traded on the NYSE and FWB and is a component of the Russell 1000 and DAX indices. The company reported a revenue of $1.97 billion and an operating income of $410 million in 2023. QIAGEN's impact is significant in the biotechnology industry, providing crucial tools and insights that advance scientific research and improve healthcare outcomes globally.